Stockscreener 앱 받기
0.3701
8.28%
-0.0334
시간 외 거래:
.36
-0.0101
-2.73%
전일 마감가:
$0.4035
열려 있는:
$0.3667
하루 거래량:
3.04M
Relative Volume:
1.40
시가총액:
$60.59M
수익:
-
순이익/손실:
$-101.17M
주가수익비율:
-0.3559
EPS:
-1.04
순현금흐름:
$-96.57M
1주 성능:
-44.19%
1개월 성능:
-28.76%
6개월 성능:
-60.14%
1년 성능:
-53.52%
1일 변동 폭
$0.3595
$0.3899
1주일 범위
$0.2612
$0.68
52주 변동 폭
$0.2612
$1.60
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
명칭
X 4 Pharmaceuticals Inc
전화
857-529-8300
주소
61 NORTH BEACON STREET, BOSTON, MA
XFOR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| XFOR | 0.3701 | 60.59M | 0 | -101.17M | -96.57M | -1.04 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-08-30 | 재개 | B. Riley Securities | Buy |
| 2022-12-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-12 | 개시 | Piper Sandler | Overweight |
| 2019-12-23 | 개시 | Oppenheimer | Outperform |
| 2019-12-18 | 개시 | ROTH Capital | Buy |
| 2019-12-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-12-05 | 개시 | B. Riley FBR | Buy |
| 2019-06-07 | 개시 | Stifel | Buy |
| 2019-06-05 | 개시 | Cowen | Outperform |
모두보기
X 4 Pharmaceuticals Inc 주식(XFOR)의 최신 뉴스
HC Wainwright Analysts Reduce Earnings Estimates for XFOR - MarketBeat
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q3 2024 Earnings Call Transcript - Insider Monkey
RFK Jr vow to purge FDA sets up collision with Big Pharma - Reuters.com
Moderna, Lily, Novavax, and Pfizer stocks fall after Trump nominates RFK Jr. as health secretary - Fast Company
Earnings call: X4 Pharmaceuticals reports progress in CN treatment By Investing.com - Investing.com Nigeria
CANbridge Pharmaceuticals Inc. (HKG:1228) Not Doing Enough For Some Investors As Its Shares Slump 28% - Simply Wall St
XFOR: Positive Results for Phase 2 Trial of Mavorixafor in Chronic Neutropenia… - Zacks Small Cap Research
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer's Pipeline - Quantisnow
X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference - Yahoo Finance
Layoff Tracker: Sensei to Cut 46% of Workforce, Close Research Site - BioSpace
X4 Pharmaceuticals Inc (XFOR) Q3 2024 Earnings Call Highlights: Strategic Engagement and ... - Yahoo Finance
X4 Pharmaceuticals: Q3 Earnings Snapshot - Houston Chronicle
Stifel cuts X4 Pharmaceuticals target to $4, maintains Buy - Investing.com
X4 Pharmaceuticals: Promising Phase 2 Trial Results - TipRanks
X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
X4 Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) - Marketscreener.com
Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Rating Upgraded by StockNews.com - Defense World
Xenon Reports Q3 2024 Financial Results and Business Update - The Manila Times
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - Quantisnow
Great week for X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) institutional investors after losing 18% over the previous year - Simply Wall St
X4 Pharmaceuticals Inc (XFOR) Has A Gold Mine On Its Hands - Stocks Register
Global Respiratory Disease Testing Market to Grow at a CAGR of ~4% by 2030 | DelveInsight - The Malaysian Reserve
C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market - GlobeNewswire
Ionis to present at upcoming investor conferences - Quantisnow
Glenmark Pharmaceuticals Ltd. Sees -4.19% Decline in Stock Price, Rated 'Hold' by MarketsMOJO - MarketsMojo
DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business Update - Quantisnow
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results - GlobeNewswire
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome - The Malaysian Reserve
Global Molecular Modeling Market to Hit USD 19.47 Billion by 2032, Driven by Demand for Drug Discovery Innovation and Advanced Computational Tools | Research by SNS Insider - 新浪香港
X4 Pharmaceuticals (XFOR) to Release Earnings on Wednesday - MarketBeat
Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition - Quantisnow
Vanguard Group Inc's Strategic Acquisition in X4 Pharmaceuticals Inc - GuruFocus.com
Top 50 Pharma: Oncology patent leaders 2024 - Drug Discovery & Development
Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE - Quantisnow
H.C. Wainwright reiterated coverage on Viking Therapeutics with a new price target - Quantisnow
Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors - The Manila Times
Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024 - PR Newswire
Sun Pharma shares tumble 4% as US court blocks Leqselvi launch - The Economic Times
ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split - The Manila Times
9 Best Biotech Stocks Of November 2024 - Forbes
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - cnhinews.com
2024's 10 Best-Performing Stocks | Investing - U.S News & World Report Money
Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome - The Bakersfield Californian
Hypothyroidism Market to Expand by USD 789.8 Million (2024-2028) as New Drug Approvals Drive Revenue; Report Highlights AI's Role in Market TransformationTechnavio - The Malaysian Reserve
Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting - Business Wire
MIRA Pharma up 27% on ketamine analogue’s preclinical results for chemotherapy pain - Mugglehead
Acute Respiratory Distress Syndrome (ARDS) Market Statistics, Emerging Trends, Key Drivers And Forecast To ... - WhaTech
SEC Form 424B5 filed by Eledon Pharmaceuticals Inc. - Quantisnow
X 4 Pharmaceuticals Inc (XFOR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):